<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942029</url>
  </required_header>
  <id_info>
    <org_study_id>16304</org_study_id>
    <secondary_id>I7S-MC-HBEF</secondary_id>
    <nct_id>NCT03942029</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of LY3154207 in Healthy Participants</brief_title>
  <official_title>Safety and Tolerability of LY3154207 in Combination With a CYP3A4 Inhibitor and Assessment of Pharmacokinetics of LY3154207 After Administration of Capsule and Tablet Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety and side effects of
      LY3154207 and fluconazole (anti-fungal medication), when taken together by healthy
      participants. The study will last from nine to 11 weeks for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2019</start_date>
  <completion_date type="Actual">December 28, 2019</completion_date>
  <primary_completion_date type="Actual">December 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The capsule versus tablet formulation comparison will be open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Baseline up to 11 weeks</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Blood Pressure (BP)</measure>
    <time_frame>Baseline, up to 48 hours post dose when LY3154207 is co-administered with fluconazole</time_frame>
    <description>BP measured by ambulatory blood pressure monitoring (ABPM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate (PR)</measure>
    <time_frame>Baseline, up to 48 hours post dose when LY3154207 is co-administered with fluconazole</time_frame>
    <description>PR measured by ABPM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3154207</measure>
    <time_frame>Baseline up to 48 hours postdose</time_frame>
    <description>PK: Cmax of LY3154207</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Time Zero to Time T, where T is the Last Sample with a Measurable Concentration (AUC[0-tlast]) of LY3154207</measure>
    <time_frame>Baseline up to 48 hours postdose</time_frame>
    <description>PK: AUC(0-tlast) of LY3154207</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3154207</measure>
    <time_frame>Baseline up to 48 hours postdose</time_frame>
    <description>PK: AUC(0-inf) of LY3154207</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Part A - LY3154207 Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 capsule (reference) administered orally, once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Part A - LY3154207 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 tablet (test) administered orally, once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Part B LY3154207 (Dose 1) + Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 (dose 1) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Part B - Placebo + Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered alone, orally, once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - LY3154207 (Dose 2) + Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 (dose 2) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Placebo + Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - LY3154207 + Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3154207 (dose 2) administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Placebo + Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3154207 Capsule</intervention_name>
    <description>Administered orally as capsule</description>
    <arm_group_label>Cohort 1 Part A - LY3154207 Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3154207 Tablet</intervention_name>
    <description>Administered orally as tablet</description>
    <arm_group_label>Cohort 1 Part A - LY3154207 Tablet</arm_group_label>
    <arm_group_label>Cohort 1 Part B LY3154207 (Dose 1) + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 2 - LY3154207 (Dose 2) + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 3 - LY3154207 + Fluconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally as tablet</description>
    <arm_group_label>Cohort 1 Part B - Placebo + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 2 - Placebo + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 3 - Placebo + Fluconazole</arm_group_label>
    <other_name>Placebo Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole Tablet</intervention_name>
    <description>Administered orally as tablet</description>
    <arm_group_label>Cohort 1 Part B - Placebo + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 1 Part B LY3154207 (Dose 1) + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 2 - LY3154207 (Dose 2) + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 2 - Placebo + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 3 - LY3154207 + Fluconazole</arm_group_label>
    <arm_group_label>Cohort 3 - Placebo + Fluconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a body mass index (BMI) of 18 to 35 kilogram per meter square (kg/mÂ²)

          -  Have clinical laboratory test results within acceptable range for the population

        Exclusion Criteria:

          -  Have consumed grapefruits or grapefruit-containing products, Seville oranges or
             Seville orange-containing products, star fruits or star fruit-containing products
             within 7 days prior to dosing or intend to consume during the study

          -  Intend to use over-the-counter or prescription medication (with exception of hormonal
             contraceptives and acetaminophen), including herbal preparations containing St. John's
             wort, kava, garlic, ginger, ginkgo biloba, or guarana, within 14 days prior to
             Check-in and during the study

          -  Use of any drugs or substances that are known inducers and/or inhibitors of cytochrome
             P450 (CYP) 3A within 14 days prior to the administration of study drug and during the
             study

          -  Have evidence of active renal disease (eg, diabetic renal disease, polycystic kidney
             disease) or an estimated creatinine clearance of &lt; 80 milliliters per minute
             (mL/minute), calculated using the Chronic Kidney Disease Epidemiology Collaboration
             equation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 15, 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

